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Tumor cells frequently display an abnormal number of chromosomes, a phenomenon known as
aneuploidy. Tang et al. (2011) now show that aneuploid cells are particularly sensitive to
compounds that induce proteotoxic and energy stress. Could this vulnerability lead to new cancer
therapies?More than a century ago, the German
zoologist Theodor Boveri suggested that
most chromosome combinations that
deviate from the norm (aneuploidy) lead
to cell death. But he also predicted that
some abnormal chromosome distribu-
tions promote unrestrained proliferation
and tumor formation (Holland and Cleve-
land, 2009). Although about 90% of all
solid human tumors contain numerical
chromosome aberrations (Weaver and
Cleveland, 2006), the extent to which
aneuploidy contributes to tumor develop-
ment remains a matter of debate
(Schvartzman et al., 2010; Weaver et al.,
2007). This discussion has overshadowed
efforts to address a related but no less
important question—can aneuploidy be
targeted for cancer therapy? In this issue,
Tang et al. (2011) provide evidence that
specific cellular stress resulting from
chromosome imbalances can indeed be
utilized for killing cancer cells.
Earlier work in yeast or primary mouse
embryonic fibroblasts (MEFs) indicates
that just one extra chromosome results
in important proliferative defects, as well
as metabolic and energetic aberrations
(Torres et al., 2007; Williams et al.,
2008). These alterations are thought to
result from the additional load of proteins
encoded by the extra chromosomes.
Based on these findings, it has been
proposed that cells respond to the aneu-
ploid state by engaging protein degrada-
tion and folding pathways to correct the
protein overload caused by the chromo-
some imbalance. This cellular response
is called proteotoxic stress, and it is
accompanied by additional energetic
requirements. Whether energy and pro-teotoxic stress can be targeted as drug-
gable, nononcogene addiction pathways
represents the starting point of the inves-
tigation reported by Tang et al.
By using euploid or aneuploid MEFs
carrying Robertsonian fusion chromo-
somes, the authors investigate whether
aneuploid cells are uniquely sensitive to
a variety of compounds targeting different
pathways. A few compounds are actually
poorly tolerated by euploid cells, suggest-
ing that extra copies of genes in aneuploid
cells might be protective against a partic-
ular drug’s toxic effects. Interestingly, the
autophagy inhibitor chloroquine, the heat
shock protein 90 (Hsp90) inhibitor
17-AAG, and the inducer of the AMP-acti-
vated protein kinase (AMPK) AICAR dis-
played increased selectivity against
trisomic MEFs. Two of these molecules,
AICAR and 17-AAG, also display some se-
lectivity against chromosomally unstable
MEFs with specific alterations in BubR1
or Cdc20, two proteins whose precise
regulation controls fidelity during chromo-
some segregation (Baker et al., 2005). In
addition, AICAR and 17-AAGaremore effi-
cient at inhibiting the proliferation of human
colorectal cancer cell lines with chromo-
somal instability when compared to similar
tumor cells with microsatellite instability.
Comparable results are also found in aneu-
ploid lung tumor cells. Interestingly, all of
these aneuploid tumor cells displayed
marked sensitivity against the combination
of these molecules at low doses (Tang
et al., 2011).
What do these inhibitors have in
common, andwhy do they affect the prolif-
eration of aneuploid cells? The answer is
the selective triggering of apoptosis. InCell 144,primaryaneuploidcells, theeffectofAICAR
is mediated through its target, AMPK. This
kinase phosphorylates p53 on serine 15,
and the subsequent stabilization of this
tumor suppressor results in the induction
of proapoptotic Bax. However, p53 is also
activated by other compounds that do not
show selectivity against aneuploid MEFs.
In addition, AICAR and 17-AAG are simi-
larly effective inp53null human tumor cells.
In search of an explanation for these
results, Tang et al. analyze several markers
of the cellular stress induced by aneu-
ploidy. For instance, aneuploid cells
express higher levels of two mediators of
autophagy, LC3 and Bnip3, as well as
increased levels of Hsp72, a chaperone
involved in protein folding. Treatment with
AICAR results in a further increase in the
level of these markers in aneuploid cells
compared to euploid cells. These results
suggest that the selectivity of a given drug
relies on its capacity to synergize with the
basal stress levels existing in aneuploid
cells. This suggestion is in agreement with
the fact that the effect of AICAR, 17-AAG,
or the combination of both directly corre-
lates with the size of the additional
chromosome and therefore depends on
the protein overload in aneuploid cells.
The results by Tang et al. support the
argument that compounds thatexacerbate
the basal stress state exhibited by aneu-
ploid cells could be effective against aneu-
ploid tumors, irrespective of their origin or
their p53 status. Both AICAR and 17-AAG
display some toxicity against euploid cells.
However, at low concentrations, they can
synergize with basal proteotoxic and
energy stress present in aneuploid cells,
thus opening a window of opportunity forFebruary 18, 2011 ª2011 Elsevier Inc. 465
Figure 1. Therapeutic Opportunities Arising from Aneuploidy
The unbalanced protein load in aneuploid cells may result in energy and pro-
teotoxic stress that increase the susceptibility of these cells to apoptotic
death. Due to this basal level of stress, these aneuploid cells aremore sensitive
to specific small molecule compounds that target these pathways, such as the
stress-inducing agent AICAR or the protein folding inhibitor 17-AAG. The
sensitivity of cells to these drugs is likely to be proportional to the increased
protein load in highly aneuploid cells, a condition that is frequently present in
human tumors or that may be forced with drugs that prevent fidelity during
chromosome segregation. The differential sensitivity of these cells to stress-
inducing compounds provides a new window of opportunity for specifically
targeting cancer cells.specific treatments against
tumor cells (Figure 1). Given
that the basal stress depends
on the protein overload, these
drugs are likely to be more
effective in highly aneuploid
cells, a feature ofmanyhuman
cancers (Weaver and Cleve-
land, 2006). Yet, whether
energy and proteotoxic stress
are a general feature of aneu-
ploid cells needs to be further
tested in different human
tumors. The recent finding
that aneuploid yeast strains
proliferate better in some
culture conditions (Pavelka
et al., 2010) suggests that
tumor cells could select aneu-
ploid compositions favorable
for their growth in vivo. Thus,
the effect of AICAR or
17-AAG, or of other small
molecules targeting these
pathways, needs to be tested
in each specific tumor type.For instance, both AICAR and 17-AAG
were effective against aneuploid colorectal
tumor cells, whereas only a subset of lung
tumor cells were sensitive to AICAR (Tang
et al., 2011), suggesting that not all aneu-
ploidies are equal. A meta-analysis of
gene expression profiles in aneuploid
versus euploid tumor cells may help to
identify markers of the proteotoxic
response and perhaps predict the effect
of these drugs on different tumor types.
In addition, the correlation between the
efficacy of these drugs and protein over-
load should also be tested in vivo using
cancer cells engineered to harbor different
chromosome compositions. If these466 Cell 144, February 18, 2011 ª2011 Elsevresults are confirmed, one could predict
that treating cancer cells with drugs that
increase aneuploidy by preventing chro-
mosome alignment or by abrogating the
mitotic checkpoint could synergize with
drugs against the proteotoxic and energy
stress induced by aneuploidy (Figure 1).
The inhibition of chromosome alignment
induced by microtubule poisons such as
taxol may have such an effect. Also, abro-
gation of the mitotic checkpoint by using
BubR1 or Mps1 kinase inhibitors may
represent an alternative mechanism. In
fact, taxol and Mps1 downregulation
cooperate to elevate the frequency ofmis-
segregation of chromosomes in tumorier Inc.cells (Janssen et al., 2009).
Whether AICAR and 17-AAG
might synergize with microtu-
bule poisons ormitotic check-
point abrogators remains to
be tested. It will be crucial in
future work to further explore
these or other therapeutic
opportunities afforded by the
energy and proteotoxic stress
present in aneuploid cells.
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